Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that it has successfully completed its previously announced acquisition of Synageva BioPharma Corp.
Trade-Ideas LLC identified Synageva BioPharma (GEVA) as a new lifetime high candidate
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp.
Biotech stocks are one of the hottest investment areas these days, but not all biotech stocks are smart buys.
Acquisitions cut into overabundance of companies.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Synageva BioPharma Corp.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Synageva BioPharma Corp.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Synageva...
Trade-Ideas LLC identified Synageva BioPharma (GEVA) as an unusual social activity candidate
The Fed chief used some pretty frightening terms about stocks Wednesday, saying that valuations 'generally are quite high' and that there are 'potential dangers' with them.
Investors see Alexion's willingness to write a huge check for Synageva as a tacit acknowledgment that Soliris' long-term future might be more at risk than the company lets on.
U.S. stocks fell for a second straight session.
Stocks pared losses, though remained in the red by close as markets weighed comments from Federal Reserve Chair Janet Yellen that equity valuations were possibly stretched.
Stocks slump in the final hour of trading as markets weigh comments from Federal Reserve Chair Janet Yellen that warned of potentially overstretched equity valuations.
The Fast Money trading panel discussed whether biotech is in a bubble about to burst and weighed in on comments made by Cablevision's CEO on consolidating the New York Market.
Stocks are trading close to session lows by mid-afternoon Wednesday
Shares of Synageva Biopharma (GEVA) more than doubled to a 52-week high of $215.74 on Wednesday after Alexion Pharmaceuticals ALXN agreed to acquire it for $8.4 billion.
It's not the Fed chief's place.
Here's how to trade some of the most active stocks on the market right now.
Stocks pare losses by mid-morning Wednesday in a volatile day of trading.
Herbalife (HLF) rallied after boosting full-year earnings forecasts as sales in China showed strength.
The cash and stock deal values Synageva at $230 per share, based on Alexion's average closing price for the past nine days.
